Phase II Evaluation of Intravenous Paclitaxel, Intraperitoneal Cisplatin, Intravenous Liposomal Doxorubicin and Intraperitoneal Paclitaxel in Women With Optimally-Debulked Stage III Epithelial Ovarian Cancer

Study start date: September 1, 1999

DISEASE CHARACTERISTICS: Histologically confirmed stage III ovarian epithelial, fallopian tube, or primary peritoneal carcinoma Tumor involves one or both ovaries with microscopically confirmed peritoneal metastasis outside the pelvis and/or regional lymph node metastasis No tumors of borderline or low malignant potential only Mixed Mullerian tumors allowed Must have optimal disease defined as no residual lesions after resection or residual disease such that no single lesion measures greater than 1 cm in diameter Must have undergone staging exploratory laparotomy with tumor debulking within the past 70 days PATIENT CHARACTERISTICS: Age: Not specified Performance status: SWOG 0-1 Life expectancy: Not specified Hematopoietic: Granulocyte count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Hepatic: Bilirubin ≤ 2 times upper limit of normal (ULN) SGOT or SGPT ≤ 2 times ULN Renal: Creatinine clearance ≥ 50 mL/min Cardiovascular: No congestive heart failure No cardiac arrhythmia No myocardial infarction or unstable angina within the past 6 months Patients with a history of myocardial disease must not have ischemia or pathologic arrhythmias and must have an ejection fraction > 50% by MUGA Other: Not pregnant or nursing Fertile patients must use effective contraception No active or uncontrolled infection No concurrent fever No grade 2 or greater sensory neuropathy No severe gastrointestinal symptoms (i.e., partial obstruction) and/or bleeding, diarrhea, or abdominal tenderness suggestive of peritoneal irritation or infection No erythema or tenderness of abdominal incision or port site suggestive of underlying infection No other malignancy within the past five years except adequately treated basal cell or squamous cell skin cancer or carcinoma in situ of the cervix PRIOR CONCURRENT THERAPY: Biologic therapy: No prior immunotherapy for ovarian cancer Chemotherapy: No prior chemotherapy for ovarian cancer Endocrine therapy: Not specified Radiotherapy: No prior pelvic radiotherapy for ovarian cancer Surgery: See Disease Characteristics Recovered from all reversible surgery-related toxic effects Other: No other concurrent antitumor treatment No concurrent antibiotics for infection of undetermined etiology